0001144204-17-056175.txt : 20171103 0001144204-17-056175.hdr.sgml : 20171103 20171103160554 ACCESSION NUMBER: 0001144204-17-056175 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20171103 FILED AS OF DATE: 20171103 DATE AS OF CHANGE: 20171103 FILER: COMPANY DATA: COMPANY CONFORMED NAME: GW PHARMACEUTICALS PLC CENTRAL INDEX KEY: 0001351288 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35892 FILM NUMBER: 171176446 BUSINESS ADDRESS: STREET 1: SOVEREIGN HOUSE STREET 2: VISION PARK CITY: HISTON, CAMBRIDGE CB24 9BZ STATE: X0 ZIP: 00000 BUSINESS PHONE: 44 1223 266800 MAIL ADDRESS: STREET 1: SOVEREIGN HOUSE STREET 2: VISION PARK CITY: HISTON, CAMBRIDGE CB24 9BZ STATE: X0 ZIP: 00000 6-K 1 tv478581_6k.htm FORM 6-K

 

 

United States

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

  

Form 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the Month of November, 2017

 

Commission File Number: 001-35892  

 

GW PHARMACEUTICALS PLC

(Translation of registrant’s name into English)

  

Sovereign House

Vision Park

Histon

Cambridge CB24 9BZ

United Kingdom

(Address of principal executive offices)

 

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F  x   Form 40-F  ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

 

Yes  ¨   No  ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

 

Yes  ¨   No  ¨

 

 
 

 

 

 

 

 

  

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

On November 1, 2017, Dr. Geoffrey Guy, Chairman of GW Pharmaceuticals plc (the “Company”) and Justin Gover, the Company’s Chief Executive Officer sold American Depositary Shares under their respective Rule 10b5-1 plans. Details of the sales (“Transaction Details”) are set forth in Exhibit 99.1 hereto and are incorporated by reference herein. The information contained in Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, unless expressly set forth by specific reference in such a filing.

 

Exhibits

 

99.1       Transaction Details.

  

 

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  GW Pharmaceuticals plc
     
  By: /s/ Adam George
  Name: Adam George
  Title: Company Secretary
     
Date: November 3, 2017    

 

 

 

 EX-99.1 2 tv478581_ex99-1.htm EXHIBIT 99.1

Exhibit 99.1

 

Notification and public disclosure of transactions by persons discharging

 

managerial responsibilities and persons closely associated with them

 

1.          Details of the person discharging managerial responsibilities / person closely associated
a.          Name Justin Gover
2.          Reason for the notification
a.          Position/status Chief Executive Officer
b.         

Initial notification

 

/Amendment

 

 Initial notification
3.          Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.          Name GW Pharmaceuticals PLC
b.          LEI  
4.          Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.         

Description of the

 

Financial instrument, type of instrument

 

Identification code

 

 

 

American Depositary Shares

 

ISIN: 36197T1034

 

b.          Nature of the transaction Exercise of Long Term Incentive Plan options and sale of resulting American Depositary Shares an accordance with 10b5.1 plan dated 30 August 2017
c.          Price(s) and volume(s)   Price(s)  $107.89 Volume(s) 889   ADS’s sold
d.         

Aggregated information

 

·Aggregated volume

 

·Price

 

 

 

 

 

n/a

 

e.          Date of the transaction November 1, 2017
f.          Place of the transaction Nasdaq, New York

 

 

 

 

 

1.          Details of the person discharging managerial responsibilities / person closely associated
a.          Name Dr Geoffrey Guy
2.          Reason for the notification
a.          Position/status Chairman
b.         

Initial notification

 

/Amendment

 

 Initial notification
3.          Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.          Name GW Pharmaceuticals PLC
b.          LEI  
4.          Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.         

Description of the

 

Financial instrument, type of instrument

 

Identification code

 

 

 

American Depositary Shares

 

ISIN: 36197T1034

 

b.          Nature of the transaction Exercise of Long Term Incentive Plan options and sale of resulting American Depositary Shares an accordance with 10b5.1 plan dated 2 October 2017
c.          Price(s) and volume(s)   Price(s)  $109.53 Volume(s) 10,671   ADS’s sold
d.         

Aggregated information

 

·Aggregated volume

 

·Price

 

 

 

 

 

n/a

 

e.          Date of the transaction November 1, 2017
f.          Place of the transaction Nasdaq, New York